IN THE CLAIMS:

1. (Currently Amended) A kit for detecting or measuring an analyte having bivalent or higher binding capability, the kit comprising the following receptor I, receptor II, and solid phase conjugate for capturing a complex comprising the receptor I, the receptor II and the analyte, wherein:

1) ~~a~~ receptor I is ~~represented by a compound~~ L1-B1-R1-M which is a complex of ~~comprising~~ a compound R1-M and ~~bound to~~ a compound L1-B1, the compound RI-M comprising a substance R1 bound to a marker M, the substance RI being capable of binding to a substance B1, the compound L1-B1 comprising a ligand L1 bound to the substance B1, the ligand L1 being capable of binding to the analyte A;

2) ~~a~~ receptor II is ~~represented by a compound~~ L2-B2-R2-B3 which is a complex of ~~comprising~~ a compound L2-B2 and ~~previously bound to~~ a compound R2-B3, the compound L2-B2 comprising a ligand L2 bound to ~~and~~ a substance B2 ~~introduced into the ligand L2~~, the ligand L2 being capable of binding to the analyte A, the substance B2 and analyte A ~~having different~~ binding differently with ligand L2 ~~capability from the analyte A~~, the compound R2-B3 comprising a substance R2 bound to a bond element B3, the substance R2 being capable of binding to the substance B2, the bond element B3 and substance B2 having different binding ~~differently capability~~ with R2 ~~from the substance B2~~; and

3) the solid phase conjugate is ~~represented by a compound~~ R3-solid phase,

wherein R3 is an ~~the compound R3-solid phase comprising a~~ anti-bond element R3 bound to a solid phase and ~~, the anti-bond element R3 being~~ capable of binding to the bond element B3, wherein the solid phase conjugate is stored within the kit separate from at least receptor II.

2. (Cancelled)

3. (Cancelled)

4. (Currently Amended) The kit according to claim 1, wherein the substance R1 has a plurality of binding points with respect to the substance B1, and a plurality of the ligands L1 are bound to the substance R1 through ~~by the medium of~~ the substance B1.

5. (Currently Amended) The kit according to claim 4. wherein each of the plurality of the ligands L1 have different ~~has plural~~ types of reactivity.

6. (Currently Amended) The kit according to claim 1, wherein the substance R2 has a plurality of binding points with respect to the substance B2, and a plurality of the ligands L2 ~~or ligands L3~~ are bound to the substance R2 through ~~by the medium of~~ the substance B2.

7. (Currently Amended) The kit according to claim 6, wherein ~~each of~~ the plurality

of the ligands L2 have different ~~or ligands L3 has plural~~ types of reactivity.

8. (Cancelled)

9. (Previously Presented) The kit according to claim 1, wherein the analyte A having bivalent or higher binding capability is a substance selected from the group consisting of DNAs, RNAs, antigens, and antibodies.

10. (Currently Amended) The kit according to claim 1, wherein the ligands ~~ligand~~ L1 and L2 are each ~~, ligand L2 or ligand L3 is~~ a substance selected from the group consisting of DNA, RNA, antigen, antibody, lectin, glycoprotein, and sugars ~~sugar~~.

11. (Previously Presented) The kit according to claim 1, wherein the ligand L1 and the ligand L2 are the same substance.

12. (Currently Amended) The kit according to claim 1, wherein analyte A is DNA or RNA and the ligands L1 and L2 ~~and the ligand L3~~ are substances having different sequences respectively complementary to different portions of the analyte A ~~with one another~~.

13. (Currently Amended) The kit according to claim 1, wherein the binding capability between the substance B1 and the substance R1 or between the

substance B2 and the substance R2 is represented by a dissociation constant of from 10^{-8} to 10^{-16} ~~(M)~~.

14. (Previously Presented) The kit according to claim 1, wherein the substance B1 and/or the substance B2 is biotin.

15. (Currently Amended) The kit according to claim 1, wherein the substance Bl and/or the substance B2 is a substance selected from the group consisting of DNA, RNA, antigen, antibody, lectin, glycoprotein, and sugars ~~sugar~~.

16. (Previously Presented) The kit according to claim 1, wherein the substance R1 and/or the substance R2 is a substance selected from the group consisting of streptavidin and avidin.

17. (Currently Amended) The kit according to claim 1, wherein the substance R1 and/or the substance R2 is a substance selected from the group consisting of antigen, antibody, DNA, RNA, lectin, glycoprotein, and sugars ~~sugar~~.

18. (Original) The kit according to claim 1, wherein the substance R1 and the substance R2 are the same substance.

19. (Original) The kit according to claim 1, wherein the substance R1 and the

substance R2 are different substances.

20. (Previously Presented) The kit according to claim 1, wherein the bond element B3 is bondable to the anti-bond element R3 by complementary binding of at least part of DNAs or RNAs.

21. (Previously Presented) The kit according to claim 1, wherein the marker M is a substance selected from the group consisting of coloring dye, fluorescent dye, luminescent substance, metal colloid, latex, liposome, radioactive isotope, enzyme, DNA, and RNA.

22. (Previously Presented) The kit according to claim 1, wherein the solid phase is a substance selected from the group consisting of polystyrene, nitrocellulose, nylon, cellulose, and glass.

23. (Currently Amended) A method for detecting or measuring an analyte A having bivalent or higher binding capability, the method comprising the steps of:

bringing ~~1)~~ the analyte A into contact with, as discrete reactants, receptor I and receptor II, wherein receptor I is ~~contact with 2) a receptor I represented by a compound~~ L1-B1-R1-M which is a complex of ~~comprising~~ a compound R1-M and ~~bound to~~ a compound L1-B1, the compound R1-M comprising a substance R1 bound to a marker M, the substance R1 being capable of binding to a substance

B1, the compound L1-B1 comprising a ligand L1 bound to the substance B1, the ligand L1 being capable of binding to the analyte A; and ~~3)~~ a receptor II represented by a compound L2-B2-R2-B3 comprising a compound L2-B2 previously bound to a compound R2- B3, the compound L2-B2 comprising a ligand L2 and a substance B2 introduced into the ligand L2, the ligand L2 being capable of binding to the analyte A, the substance B2 and analyte A ~~having different~~ binding differently with ligand L2 ~~capability from the analyte A~~, the compound R2-B3 comprising a substance R2 bound to a bond element B3, the substance R2 being capable of binding to the substance B2, the bond element B3 and substance B2 having different binding with R2; ~~having binding capability different from the substance B2,~~

allowing receptor I, receptor II and analyte A to react with one another to thereby form an analyte ~~a~~ complex comprising receptor I, receptor II and analyte A;

~~4)~~ allowing a solid phase conjugate to capture the analyte ~~formed~~ complex, wherein the solid phase conjugate is ~~represented by~~ a compound R3-solid phase and R3 is an anti-bond element bound to the solid phase and ~~, the compound R3-solid phase comprising a anti-bond element R3 bound to a solid phase, the anti-bond element R3 being~~ capable of binding to the bond element B3, and

~~5)~~ detecting or measuring the marker M in the captured complex.

24. (Cancelled)

25. (Cancelled)

26. (New) The method according to claim 23 wherein said marker is detected as a colored mark on the solid phase.

27. (New) The method according to claim 26 wherein said colored mark is a line.

28. (New) The kit according to claim 1 wherein said receptor I and receptor II are present in said kit as discrete substances.